Ddavp Spray
Designed to support water retention to manage central diabetes insipidus and alleviate nighttime bedwetting.
- Categories
- Diabetes Management · Hormone Therapy
- Active ingredient
- Desmopressin
- Route
- Nasal use
- Form
- Nasal Spray
- Strengths
- 10mcg 2.5ml
Prescription and consultation requirements for Ddavp Spray vary by destination and are determined by the fulfilment partner.
Ddavp Spray details
- Conditions
- Central Diabetes Insipidus · Primary Nocturnal Enuresis
- Alternative names
- desmopressin acetate
- Therapeutic class
- Synthetic Vasopressin Analog
- Pharmacological class
- Antidiuretic Hormone
- Contraindications
- hyponatraemia; severe renal impairment; congestive heart failure
- Minor side effects
- headache; nasal congestion; nausea
- Moderate side effects
- hyponatraemia; mild abdominal pain; flushing
- Dosage forms
- Nasal Spray
- Administration route
- Nasal use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Ferring Pharmaceuticals
- Onset Time
- 1 hour
- Duration
- 8–12 hours
- Storage instructions
- Store between 2°C and 8°C.
- Drug interactions
- NSAIDs; Carbamazepine; SSRIs
- Age restrictions
- Approved for children over six years and adults.
Serious side effects
severe water intoxication, requires immediate medical attention; severe hyponatraemic seizures, requires immediate medical attention
Patient summary
designed to support water retention to manage central diabetes insipidus and alleviate nighttime bedwetting.
Mechanism of action
Binds to V2 receptors in renal collecting ducts, increasing water permeability and subsequent fluid reabsorption.
Pregnancy and breastfeeding
TGA Category B: Safety verified in human registry databases. Breastfeeding: Compatible.